AIM: Despite several attempts made during the last decade, the exact pathogenesis of exceedingly high thrombotic events and bad obstetric outcome in antiphospholipid syndrome (APS) remains elusive. Anti-annexin A5 (aANX IgG) is thought to have a role in pathophysiology of APS. We studied role of aANX IgG in the pathogenesis of hypercoagulable state in APS patients. METHODS: We estimated levels of aANX IgG in 112 patients with APS (86 primary and 26 secondary). We also estimated aANX IgG levels in 40 age- and sex-matched healthy controls, 10 patients with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) each, without any history of thrombosis or pregnancy morbidity, 10 patients of non-APS thrombosis and 10 patients of pregnancy loss without APS. RESULTS: Only three healthy controls, two SLE (P = 0.239), one RA patient (P = 0.794), three non-APS thrombosis patients (P = 0.086) and two patients with pregnancy loss without APS (P = 0.258) had marginally elevated values, whereas 53 primary APS (P < 0.001) and 16 secondary APS (P < 0.001) were positive. We also compared aANX IgG levels in different groups. Mean ± standard errors of the mean of healthy controls was 3.77 ± 0.49, in SLE patients it was 4.88 ± 1.17 (P = 1.000), in RA patients it was 4.67 ± 0.97 (P = 1.000), in non-APS thrombosis it was 7.93 ± 0.88 (P = 0.488) and in pregnancy loss without APS it was 6.80 ± 0.93 (P = 0.789). However, it was significantly elevated in primary APS (12.87 ± 1.07, P < 0.001), secondary APS (11.98 ± 1.41, P = 0.001) and total APS patients (12.68 ± 0.88, P < 0.001). CONCLUSION: From the above observations it appears that aANX IgG plays a significant role in producing a hypercoagulable state in primary and secondary APS.
AIM: Despite several attempts made during the last decade, the exact pathogenesis of exceedingly high thrombotic events and bad obstetric outcome in antiphospholipid syndrome (APS) remains elusive. Anti-annexin A5 (aANX IgG) is thought to have a role in pathophysiology of APS. We studied role of aANX IgG in the pathogenesis of hypercoagulable state in APSpatients. METHODS: We estimated levels of aANX IgG in 112 patients with APS (86 primary and 26 secondary). We also estimated aANX IgG levels in 40 age- and sex-matched healthy controls, 10 patients with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) each, without any history of thrombosis or pregnancy morbidity, 10 patients of non-APS thrombosis and 10 patients of pregnancy loss without APS. RESULTS: Only three healthy controls, two SLE (P = 0.239), one RApatient (P = 0.794), three non-APS thrombosispatients (P = 0.086) and two patients with pregnancy loss without APS (P = 0.258) had marginally elevated values, whereas 53 primary APS (P < 0.001) and 16 secondary APS (P < 0.001) were positive. We also compared aANX IgG levels in different groups. Mean ± standard errors of the mean of healthy controls was 3.77 ± 0.49, in SLEpatients it was 4.88 ± 1.17 (P = 1.000), in RApatients it was 4.67 ± 0.97 (P = 1.000), in non-APS thrombosis it was 7.93 ± 0.88 (P = 0.488) and in pregnancy loss without APS it was 6.80 ± 0.93 (P = 0.789). However, it was significantly elevated in primary APS (12.87 ± 1.07, P < 0.001), secondary APS (11.98 ± 1.41, P = 0.001) and total APSpatients (12.68 ± 0.88, P < 0.001). CONCLUSION: From the above observations it appears that aANX IgG plays a significant role in producing a hypercoagulable state in primary and secondary APS.